Atlas Trials

Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma

Clinical trial NCT04887025 · UNKNOWN

Trial details

NCT number
NCT04887025
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory B-cell Lymphoma
Start date
2022-02-08
Primary completion
2023-03-15
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.